D Orazio & Associates Inc. Invests $218,000 in Cencora, Inc. $COR

D Orazio & Associates Inc. purchased a new stake in shares of Cencora, Inc. (NYSE:COR) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 728 shares of the company’s stock, valued at approximately $218,000.

Other hedge funds have also bought and sold shares of the company. Invesco Ltd. grew its holdings in Cencora by 42.1% in the first quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock worth $1,281,429,000 after purchasing an additional 1,364,433 shares during the period. T. Rowe Price Investment Management Inc. boosted its position in shares of Cencora by 4,459.6% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 997,233 shares of the company’s stock worth $277,321,000 after purchasing an additional 975,362 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Cencora by 8.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock worth $2,682,821,000 after purchasing an additional 787,858 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Cencora in the 1st quarter worth approximately $181,284,000. Finally, Caisse DE Depot ET Placement DU Quebec increased its position in Cencora by 144.4% during the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 743,072 shares of the company’s stock valued at $206,641,000 after buying an additional 439,008 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling

In other news, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the transaction, the chief executive officer directly owned 37,940 shares in the company, valued at $12,398,792. This trade represents a 11.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the sale, the chairman owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 41,544 shares of company stock worth $12,230,941. 10.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Weiss Ratings reiterated a “buy (b-)” rating on shares of Cencora in a research note on Thursday, October 30th. Wells Fargo & Company raised their price target on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a report on Tuesday. Evercore ISI set a $400.00 price target on shares of Cencora and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Robert W. Baird increased their price objective on shares of Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research note on Tuesday. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $371.09.

Cencora Trading Up 0.5%

Shares of NYSE:COR opened at $365.06 on Friday. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. Cencora, Inc. has a 1 year low of $223.92 and a 1 year high of $366.17. The company has a market cap of $70.78 billion, a P/E ratio of 37.56, a PEG ratio of 1.56 and a beta of 0.63. The stock’s fifty day moving average price is $319.97 and its 200-day moving average price is $301.57.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. The business had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.Cencora’s revenue was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Sell-side analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date is Friday, November 14th. Cencora’s payout ratio is currently 30.19%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.